Objective: To describe new technologies (biomarkers and tests) used to assess and monitor the severity and progression of multiple organ dysfunction syndrome in children as discussed as part of the Eunice Kennedy Shriver National Institute of Child Health and Human Development MODS Workshop (March 26–27, 2015).
Data Sources: Literature review, research data, and expert opinion.
Study Selection: Not applicable.
Data Extraction: Moderated by an experienced expert from the field, investigators developing and assessing new technologies to improve the care and understanding of critical illness presented their research and the relevant literature.
Data Synthesis: Summary of presentations and discussion supported and supplemented by relevant literature.
Conclusions: There are many innovative tools and techniques with the potential application for the assessment and monitoring of severity of multiple organ dysfunction syndrome. If the reliability and added value of these candidate technologies can be established, they hold promise to enhance the understanding, monitoring, and perhaps, treatment of multiple organ dysfunction syndrome in children.
1Department of Pediatrics and the Steele Children’s Research Center, University of Arizona College of Medicine—Tucson, Tucson, AZ.
2Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH.
3Biomedical Engineering Department, Viterbi School of Engineering, University of Southern California, Los Angeles, CA.
4Department of Pediatrics and Communicable Diseases, C.S. Mott Children’s Hospital, and Department of Biomedical Engineering, Michigan Center for Integrated Research in Critical Care, University of Michigan, Ann Arbor, MI.
5Division of Thoracic Surgery and Critical Care Medicine, Department of Surgery, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
6Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte-Justine Hospital, Université de Montréal, Montréal, QC, Canada.
This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, the National Institutes of Health, the U.S. Department of Health and Human Services, or the U.S. government.
Dr. Wong’s institution received funding from the National Institutes of Health (NIH); he received support for article research from the NIH; and he received funding from holding U.S. Patents for sepsis stratification biomarkers. Dr. Finley received funding from NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH, and her institution received funding from NSF and from the Rose Hills Foundation. Dr. Daniels’ institution received funding from NIH (K12 Award), and he received support for article research from the NIH. Dr. Seely received funding from being a Founder and Board Chairman of Therapeutic Monitoring Systems (a company dedicated to bringing variability-directed clinical decision support software products to the bedside to improve care). He has patents related to continuous multiple organ variability analysis and is Founder and Chief Science Officer of Therapeutic Monitoring Systems, a company created to help bring variability-derived clinical decision support to the bedside to improve care. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: firstname.lastname@example.org